Overview

Iluminos Therapeutics is pioneering novel small molecule pipeline programs to address profound unmet medical needs across both central nervous system disorders and metabolic disease. Our lead clinical candidate targets Dyrk1a and its critical downstream pathways to deliver transformative, disease-modifying outcomes across four high-value indications: Alzheimer’s disease, related tauopathies, Down syndrome, and Type 1 diabetes.